

DAFTAR PUSTAKA

1. Putra Ritonga Dosen Prodi ES, Imelda Stik, Bilal Nomor J. Upaya Pencegahan Infeksi Saluran Kemih Oleh Perawat Pada Pasien Terpasangnya Kateter Di Rumah Sakit Umum Imelda Pekerja Indonesia Medan. *Jurnal Ilmiah Keperawatan IMELDA*. 2018;4(1).
2. Rezaee MA, Abdinia B. Etiology and antimicrobial susceptibility pattern of pathogenic bacteria in children subjected to UTI: A referral hospital-based study in northwest of Iran. *Medicine (United States)*. 2015;94(39):e1606.
3. Leung AKC, Wong AHC, Leung AAM, Hon KL. Urinary Tract Infection in Children. *Recent Pat Inflamm Allergy Drug Discov* [Internet]. 2019 Aug 5;13(1):2–18. Available from: <http://www.eurekaselect.com/168638/article>
4. Omar M. Aboumarzouk. Extended spectrum beta-lactamase urinary tract infections. Omar M. Aboumarzouk, editor. *Urol Ann* [Internet]. Omar M. Aboumarzouk. 2014;6(2). Available from: www.urologyannals.com
5. Shakya P, Shrestha D, Maharjan E, Sharma VK, Paudyal R. ESBL Production Among *E. coli* and *Klebsiella* spp. Causing Urinary Tract Infection: A Hospital Based Study. *Open Microbiol J*. 2017 May 4;11(1):23–30.
6. Biutifasari V. Extended Spectrum Beta-Lactamase (ESBL). *Literature Study Oceana Biomedicina Journal* [Internet]. 2018;1(1). Available from: www.wiley.com
7. Winarto. Prevalensi Kuman ESBL(Extended Spectrum Beta Lactamase)dari Material Darah di RSUP Dr. Kariadi Tahun 2004-2005. *Media Media Indonesiana*. 2009;43.
8. Dhillon RHP, Clark J. ESBLs: A clear and present danger? Vol. 2012, *Critical Care Research and Practice*. 2012.
9. Hu Y, Wang X, Tucker JD, Little P, Moore M, Fukuda K, et al. Knowledge, attitude, and practice with respect to antibiotic use among Chinese medical students: A multicentre cross-sectional study. *Int J Environ Res Public Health*. 2018 Jun 4;15(6).
10. Mantu KFK GLBW. Evaluasi Penggunaan Antibiotik Pada Pasien Infeksi Saluran Kemih Di Instalasi Rawat Inap RSUP. PROF. DR. R. D. Kandou Manadoperiode Juli 2013 -Juni 2014. *Jurnal Ilmiah Farmasi*. 2015;4.

11. Aristanti P.A. Efektivitas Terapi Antibiotik Pada Pasien Rawat Inap Penderita Infeksi Saluran Kemih DI RSD dr. Soebandi Jember Periode Januari-Desember 2014. [JEMBER]: FAKULTAS FARMASI UNIVERSITAS JEMBER ; 2015.
12. Sharif Z, Peiravian F, Salamzadeh J, Mohammadi NK, Jalalimanesh A. Irrational use of antibiotics in Iran from the perspective of complex adaptive systems: redefining the challenge. *BMC Public Health*. 2021 Dec 1;21(1).
13. Alolah H, Talal M, Shammari A, Bejad A, Mjlad A, Ashraf Tadvi N, et al. Knowledge, Attitudes and Practice Regarding Antimicrobial Resistance and Antimicrobial Use among Undergraduate Medical Students in Majmaah, Saudi Arabia [Internet]. Article in *Journal of Research in Medical and Dental Science*. 2019. Available from: <https://www.researchgate.net/publication/333841107>
14. Purnama Sari R. Angka Kejadian Infeksi Saluran Kemih (ISK) dan Faktor Resiko Yang Mempengaruhi Pada Karyawan Wanita di Universitas Lampung. Vol. 7, *Universitas Lampung Majority* |. 2018.
15. Loraine H. Prevalensi Dan Faktor Risiko Infeksi Saluran Kemih Akibat Enterobacterales Penghasil Beta Laktamase Spektrum Luas Pada Pasien Anak Di RSUP Dr Kariadi Semarang. [Semarang]: Fakultas Kedokteran UNDIP / RSUP Dr.Kariadi ; 2022.
16. Lazuardi R.S. Faktor Risiko Yang Mempengaruhi Terjadinya Bakteri Multiresisten. [Jakarta]: Universitas Islam Negeri Syarif Hidayatullah; 2019.
17. Rissa F, Hadi P, Hapsari R. FFaktor Risiko Infeksi Saluran Kemih Oleh Multi Drug Resistant Organisms Pada Pasien Yang Dirawat Di RSUP DR Kariadi. *Jurnal Media medika Muda*. 2013;
18. Rostinawati T. Pola Resistensi Antibiotik Bakteri Penyebab Infeksi Saluran Kemih di Puskesmas Ibrahim Adjie Kota Bandung. *Jurnal Sains Farmasi & Klinis*. 2021 Apr 30;8(1):27.
19. Walsh C, Collyns T. The pathophysiology of urinary tract infections. *Surgery (Oxford)*. 2020 Mar 1;38.
20. Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: A systematic literature review. Vol. 26, *Saudi Pharmaceutical Journal*. Elsevier B.V.; 2018. p. 678–84.
21. Waller TA, Pantin SAL, Yenior AL, Pujalte GGA. Urinary Tract Infection Antibiotic Resistance in the United States. Vol. 45, *Primary Care - Clinics in Office Practice*. W.B. Saunders; 2018. p. 455–66.

22. Guglietta A. Recurrent urinary tract infections in women: Risk factors, etiology, pathogenesis and prophylaxis. Vol. 12, *Future Microbiology*. Future Medicine Ltd.; 2017. p. 239–46.
23. Pulipati S, Srinivasa Babu P, Lakshmi Narasu M, Sowjanya Pulipati C, Anusha N. An overview on urinary tract infections and effective natural remedies. ~ 50 ~ *Journal of Medicinal Plants Studies*. 2017;5(6):50–6.
24. Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host–pathogen interactions and new treatment strategies. Vol. 18, *Nature Reviews Microbiology*. Nature Research; 2020. p. 211–26.
25. Rowe TA, Juthani-Mehta M. Urinary tract infection in older adults. Vol. 9, *Aging Health*. 2013. p. 519–28.
26. Soleha TU. Uji Kepekaan terhadap Antibiotik. *Juke Unila*. 2015 Mar;5:119–23.
27. Kurniawan J, Semiarty R. Pola Kepekaan Bakteri Penyebab Pneumonia terhadap Antibiotika di Laboratorium Mikrobiologi RSUP Dr. M. Djamil Padang Periode Januari sampai Desember 2011. *Jurnal Kesehatan Andalas* [Internet]. 2015;4(2). Available from: <http://jurnal.kes.kesri.ac.id/>
28. Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 Tentang Pedoman Penggunaan Antibiotik. 2021.
29. Sitompul F, Radji M, Bahtiar A. Evaluasi Penggunaan Antibiotik dengan Metode Gyssens pada Pasien Stroke Rawat Inap di RSUD Koja secara Retrospektif (Periode KJS dan BPJS) Evaluation of Antibiotic used with Gyssens Method on Stroke Inpatient at RSUD Koja using Retrospective Approach (KJS and BPJS period). *Jurnal Kefarmasian Indonesia*. 2016;6(1):30–8.
30. Akhtar A, Khan AH, Zainal H, Ahmad Hassali MA, Ali I, Ming LC. Physicians' Perspective on Prescribing Patterns and Knowledge on Antimicrobial Use and Resistance in Penang, Malaysia: A Qualitative Study. *Front Public Health*. 2020 Nov 25;8.
31. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. In: *Mayo Clinic Proceedings*. Elsevier Ltd; 2011. p. 156–67.
32. Madigan MT, Martinko JM, Parker J. *Brock biology of microorganisms*. Vol. 3. *Internatl Microbiol*; 2000. 129–134 p.
33. Schwalbe R, Steele-Moore L, C. Goodwin E. *Antimicrobial Susceptibility Testing Protocols*. 2007.
34. Duerden BI. Beta-Lactam Antibiotics in Systemic Infections*. *Phil J Microbiol Infect Dis*; 1987. 61–64 p.

35. Giguère S, Prescott JF, Dowling PM. Antimicrobial Therapy in Veterinary Medicine, Fifth Edition. 2013.
36. Fontana R, Canepari P, Lleò MM, Satta G. Mechanisms of resistance of enterococci to beta-lactam antibiotics. *European Journal of Clinical Microbiology and Infectious Diseases*. 1990;9(2):103–5.
37. Ruben Vardanyan, Victor J. Hruby. Synthesis of essential drugs. Elsevier Science. 2006.
38. Sherry F. Queener, J. Alan Webbe. Beta-lactam antibiotics for clinical use. 1986.
39. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J Biol Sci*. 2015 Jan 1;22(1):90–101.
40. Bajpai T, Pandey M, Varma M, Bhatambare GS. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. *Avicenna J Med*. 2017 Jan;07(01):12–6.
41. Oduro-Mensah D, Obeng-Nkrumah N, Bonney EY, Oduro-Mensah E, Twum-Danso K, Osei YD, et al. Genetic characterization of TEM-type ESBL-associated antibacterial resistance in Enterobacteriaceae in a tertiary hospital in Ghana. *Ann Clin Microbiol Antimicrob*. 2016 May 4;15(1).
42. Uemura M, Imataki O, Uchida S, Nakayama-Imaohji H, Ohue Y, Matsuka H, et al. Strain-specific transmission in an outbreak of ESBL-producing Enterobacteriaceae in the hemato-oncology care unit: A cohort study. *BMC Infect Dis*. 2017 Jan 5;17(1).
43. Evans BA, Amyes SGB. OXA β -lactamases. *Clin Microbiol Rev*. 2014;27(2):241–63.
44. Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. *Biomed Res Int*. 2018;2018.
45. Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: Definition, classification and epidemiology. *Curr Issues Mol Biol*. 2014;17(1):11–22.
46. Ikeda Y, Mamiya T, Nishiyama H, Koseki T, Mouri A, Nabeshima T. Risk Factors For Extended-Spectrum B-Lactamase-Producing Escherichia Coli Infection In Hospitalized Patients. Vol. 74, Nagoya J. Med. Sci. 2012.

47. Massart N, Camus C, Benezit F, Moriconi M, Fillatre P, Le Tulzo Y. Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate. *European Journal of Clinical Microbiology and Infectious Diseases*. 2020 May 1;39(5):889–95.
48. Thomson K, Eskola K, Eklund M, Suominen K, Määttä M, Junnila J, et al. Characterisation of and risk factors for extended-spectrum β -lactamase producing Enterobacterales (ESBL-E) in an equine hospital with a special reference to an outbreak caused by *Klebsiella pneumoniae* ST307:CTX-M-1. *Acta Vet Scand*. 2022 Dec 1;64(1).
49. Abu Taha A, Shtawi A, Jaradat A, Dawabsheh Y. Prevalence and Risk Factors of Extended Spectrum Beta-Lactamase-Producing Uropathogens among UTI Patients in the Governmental Hospitals of North West Bank: A Cross-Sectional Study. *Journal of Ancient Diseases & Preventive Remedies*. 2018;06(02).
50. Flokas ME, Karanika S, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in pediatric bloodstream infections: A systematic review and meta-analysis. *PLoS One*. 2017 Jan 1;12(1).
51. Gaillot O, Jouis CM, Abachin E´ R, Lecuru F, Arlet G, Simonet M, et al. Nosocomial Outbreak of *Klebsiella pneumoniae* Producing SHV-5 Extended-Spectrum-Lactamase, Originating from a Contaminated Ultrasonography Coupling Gel. *J Clin Microbiol*. 1998;36(5):1357–60.
52. Sugiyono. *Metode Penelitian Kuantitatif, Kualitatif dan R&D*. PT.Alfabet; 2016.
53. Pajariu A, Firmanti SC, Isbandrio B. *Infeksi Oleh Bakteri Penghasil Extended-Spectrum Beta-Lactamase (ESBL) Di RSUP Dr. Kariadi Semarang*. [Semarang]: Program Pendidikan Sarjana Kedokteran; 2010.
54. Notoatmodjo. *Metodologi Penelitian Kesehatan*. Rineka Cipta; 2018.
55. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate Point-Prevalence Survey of Health Care–Associated Infections. *New England Journal of Medicine*. 2014 Mar 27;370(13):1198–208.

56. Raz R, Chazan B, Kennes Y, Colodner R, Rottensterich E, Dan M, et al. Empiric Use of Trimethoprim-Sulfamethoxazole (TMP-SMX) in the Treatment of Women with Uncomplicated Urinary Tract Infections, in a Geographical Area with a High Prevalence of TMP-SMX-Resistant Uropathogens [Internet]. Vol. 34, *Clinical Infectious Diseases*. 2002. Available from: <https://academic.oup.com/cid/article/34/9/1165/461822>
57. Larramendy S, Deglaire V, Dusollier P, Fournier JP, Caillon J, Beaudeau F, et al. Risk factors of extended-spectrum beta-lactamases-producing *Escherichia coli* community acquired urinary tract infections: A systematic review. Vol. 13, *Infection and Drug Resistance*. Dove Medical Press Ltd; 2020. p. 3945–55.
58. Goyal D, Dean N, Neill S, Jones P, Dascomb K. Risk factors for community-acquired extended-spectrum beta-lactamase-producing Enterobacteriaceae infections-a retrospective study of symptomatic urinary tract infections. *Open Forum Infect Dis*. 2019 Feb 1;6(2).
59. Al-Jamei SA, Albsoul AY, Bakri FG, Al-Bakri AG. Extended-spectrum β -lactamase producing *E. coli* in urinary tract infections: A two-center, cross-sectional study of prevalence, genotypes and risk factors in Amman, Jordan. *J Infect Public Health*. 2019 Jan 1;12(1):21–5.
60. Long, Barbara C. *Perawatan Medikal Bedah*. Bandung: Yayasan Ikatan Alumni Pendidikan Keperawatan Pajajaran; 2000.
61. Di Paolo N, Capotondo L, Brardi S, Nicolai G. The self-locating peritoneal catheter: Fifteen years of experience. *Peritoneal Dialysis International*. 2010 Sep;30(5):504–5.
62. Sabbuba N, Hughes G, Stickler DJ. The migration of *Proteus mirabilis* and other urinary tract pathogens over Foley catheters. *BJU Int* [Internet]. 2002;89:55–60. Available from: 10.1046/j.1464-410X.2002.02560.x
63. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant *Escherichia coli* urinary tract infection. Vol. 38, *Annals of Pharmacotherapy*. 2004. p. 1148–52.
64. Luke Johnson, Allison Sabel MD PMC, William J. Burman MD, Rachel M. Everhart MS, Marcie Rome, Thomas D. MacKenzie MD M, et al. Emergence of Fluoroquinolone Resistance in Outpatient Urinary *Escherichia coli* Isolates. *Am J Med*. 2008;121(10):876–84.
65. Koksal E, Tulek N, Sonmezer MC, Temocin F, Bulut C, Hatipoglu C, et al. Investigation of risk factors for community-acquired urinary tract infections caused by extended-spectrum beta-lactamase *Escherichia coli* and *Klebsiella* species. *Investig Clin Urol*. 2019;60(1):46-53.

66. Quan J, Dai H, Liao W, Zhao D, Shi Q, Zhang L, et al. Etiology and prevalence of ESBLs in adult community-onset urinary tract infections in East China: A prospective multicenter study. *Journal of Infection*. 2021 Aug 1;83(2):175–81.
67. Shah P, Baral R, Agrawal CS, Lamsal M, Baral D, Khanal B. Urinary Calculi: A Microbiological and Biochemical Analysis at a Tertiary Care Hospital in Eastern Nepal. *Int J Microbiol*. 2020;2020.
68. Bratzler DW, Houck PM, Richards C, Steele L, Patchen Dellinger ; E, Fry DE, et al. Use of Antimicrobial Prophylaxis for Major Surgery Baseline Results From the National Surgical Infection Prevention Project. Vol. 140, *Arch Surg*. 2005.
69. van Kasteren MEE, Mannien J, Kullberg BJ, de Boer AS, Nagelkerke NJ, Ridderhof M, et al. Quality improvement of surgical prophylaxis in Dutch hospitals: Evaluation of a multi-site intervention by time series analysis. *Journal of Antimicrobial Chemotherapy*. 2005 Dec;56(6):1094–102.
70. Ierano C, Manski-Nankervis JA, James R, Rajkhowa A, Peel T, Thursky K. Surgical antimicrobial prophylaxis. *Aust Prescr*. 2017 Dec 1;40(6):225–9.
71. Hebert C, Gao Y, Rahman ; Protiva, Courtney ;, Dewart M, Shah N, et al. Extended-Spectrum β -Lactamase (ESBL) Producing *Escherichia coli* in Children: A Case-Control Study. *OFID [Internet]*. 2019;6. Available from: https://academic.oup.com/ofid/article/6/Supplement_2/S523/5605826
72. Shrestha A, Bajracharya AM, Subedi H, Turha RS, Kafle S, Sharma S, et al. Multi-drug resistance and extended spectrum beta lactamase producing Gram negative bacteria from chicken meat in Bharatpur Metropolitan, Nepal. *BMC Res Notes*. 2017 Nov 7;10(1).

Sekolah Pascasarjana